Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00067119
Status:
COMPLETED
Last Update Posted:
2017-09-19
First Post:
2003-08-11
Brief Title:
Aggrenox Prevention of Access Stenosis
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Study Overview
Official Title:
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GRAFT
Brief Summary:
The objective of the study is to determine whether Aggrenox Boehringer-Ingelheim prolongs primary unassisted patency in newly created arteriovenous grafts This record previously included information for both the GRAFT and FISTULA trials
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01DK058982 | NIH | None | httpsreporternihgovquickSearchU01DK058982 |